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Tbjective: Despite 50 years of lung preservation research, the optimal preservation
echnique is undefined. Using data from a national cohort, we investigated outcomes
ith different preservation methods after adult lung transplantation.
ethods: Early (30-day), late (30-day to 3-year), and overall (3-year) mortalities,
djusted for differences in donor and recipient characteristics, were compared by
sing Cox regression. Intensive care unit length of stay and the number of rejection
pisodes were secondary outcomes.
esults: Six hundred eighty-one eligible lung transplantations between July 1995 and
une 2003 were preserved with Euro–Collins solution (n  284), blood albumin (n 
39), core cooling (n  107), or low potassium dextran solution (n  151). There was
ignificantly increased use of low potassium dextran solution over time (P  .001).
nadjusted 3-year survival was similar across the groups (P  .72), with the highest
-year survival in the low potassium dextran group (62%; 95% confidence interval,
1%–72%) and the lowest in the blood albumin group (49%; 95% confidence interval,
9%–58%). Risk-adjusted early (P .70), late (P .27), and overall (P .72) survival
as similar across the groups and was not affected by ischemic time. Freedom from
eath caused by primary graft dysfunction was again highest in the low potassium
extran group (95%; 95% confidence interval, 90%–98%) and lowest in the blood
lbumin group (91%; 95% confidence interval, 85%–95%). There was no difference in
ntensive care unit length of stay. An increased incidence of rejection was apparent with
ncreasing ischemic time (P  .067).
onclusion: The methods of lung preservation in current use do not seem to affect
arly or midterm survival after transplantation, but increasing ischemic time might
redispose to increased rejection.
he early and longer-term success of lung transplantation (LTx) is confounded
by a high incidence of early and late graft failure. Five-year survival rates
approximate 50% or less.1 Primary graft failure is the predominant cause of
eath (30%) within 30 days, whereas late graft failure caused by bronchiolitis
bliterans syndrome (BOS) is the main cause of survival attrition after the first
ear.1 The quality of lung preservation might be a key determinant of both early2
nd late3 graft function.
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1313
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1
TXWithin 5 years of the clinical introduction of heart–lung
ransplantation, distant procurement became possible. Lung
schemic protection was afforded mainly by hypothermia. This
as induced either by surface cooling of the collapsed lung,
ore cooling (CC) on cardiopulmonary bypass, or flush perfu-
ion with a variety of intracellular- or extracellular-type perfu-
ates. Modified Euro–Collins (EC) solution flush, administered
t 15 mL · kg1 · min1 for a total volume of 60 mL ·
g1, became the most commonly used perfusate, whereas
thers adopted blood albumin (BA)–based preservation fluids
nd CC. Despite these techniques, increasing early mortality
ith increasing ischemic time was identified, and much sub-
equent experimental work led to the development of low
otassium dextran (LPD) solution as a potentially improved
ethod of preservation.3-7 However, comparison of outcomes
ith LPD solution versus other conventional preservation tech-
iques in the literature reveals varying results.7-10 Despite 5
ecades of clinical and laboratory research evaluating methods
f lung preservation,11-13 there have been few studies exam-
ning the effect of preservation technique on survival after
Tx. To identify differences, if any, in outcomes with current
ung preservation techniques, we analyzed data from the
nited Kingdom Cardiothoracic Transplant Audit (UKCTA).
aterials and Methods
he UKCTA is a national cohort study. Data on all lung trans-
lantation procedures in the United Kingdom have been collected
ince April 1995. Information is accrued prospectively at registra-
ion on the national waiting list, at the time of transplantation, and
t regular intervals (90 days and annually) thereafter. Follow-up
ata on survival are 100% complete, and the accuracy and consis-
ency of the data is maintained by means of regular computer-
ased and case record validation. Criteria for donor acceptance in
he United Kingdom have been described previously.14
In this study we analyzed first-time isolated lung transplanta-
ions in adults (16 years) between July 1995 and June 2003 using
ungs from cadaveric donors. Heart-lung transplantations were
xcluded. Thirty-day, 1-year, and 3-year survivals were the pri-
Abbreviations and Acronyms
BA  blood albumin
BOS  bronchiolitis obliterans syndrome
CC  core cooling
CI  confidence interval
dPGD  death caused by primary graft dysfunction
EC  Euro–Collins
IQR  interquartile range
LPD  low potassium dextran
LTx  lung transplantation
PGD  primary graft dysfunction
UKCTA United Kingdom Cardiothoracic Transplant
Auditary end points of the study. Length of stay in the intensive care d
314 The Journal of Thoracic and Cardiovascular Surgery ● Novnit and numbers of rejection episodes were secondary outcomes.
further secondary end point was death caused by primary graft
ysfunction (dPGD). This was defined as the presence of 1 of the
ollowing factors: pulmonary infiltrates in the transplanted lung or
ungs (bilateral in bilateral sequential lung transplant) on chest
adiography with a pulmonary capillary wedge pressure of less
han 18 cm H2O, PaO2/fraction of inspired oxygen ratio of less than
00 in the first 24 hours, or recipient ventilation for longer than 5
ays because of respiratory compromise (not associated with at-
lectasis or infection). Cases were excluded if death was due to
echnical problems during surgical intervention or if there was
vidence of acute or hyperacute rejection. Primary graft dysfunc-
ion (PGD) might predispose to infective complications or second-
ry organ failure, and death certificate coding might fail to attribute
eath to the primary causative factor of PGD. In view of this, case
ecords for all in-hospital deaths after LTx between July 1995 and
ecember 2002 were reviewed, and dPGD was validated by 3
ndependent analysts according to the predetermined criteria.
Ischemic time was defined as the time from donor crossclamp-
ng to reperfusion with recipient blood. For double-lung transplan-
ations, when 2 times were reported, the earliest reperfusion time
as used because these transplantations would have been done
ithout cardiopulmonary bypass. A rejection episode was defined
s a clinical event usually but not always accompanied by an
bnormal transbronchial biopsy result that resulted in augmenta-
ion of the patient’s immunosuppression. Histologic features of
ild rejection that did not lead to a change in the immunosuppres-
ive regimen and increases in immunosuppression to maintain
lood levels or other therapeutic goals were not counted.
Lung perfusion techniques were classified into 4 categories: EC
olution,15,16 BA,17,18 CC,19-21 or LPD solution.22,23 Vasodilator
rostaglandins (prostacyclin or prostaglandin E1) were used as an
djunct for all antegrade pulmonary artery flush techniques but not
C. Data on other vasodilators, including systemic nitric oxide
onors, were not available.
Donor and pretransplantation recipient characteristics were
ompared by using the 2 or Fisher exact tests (categoric data) or
he Kruskal–Wallis test (continuous data). The Fisher exact test
as chosen when greater than 20% of the expected frequencies
ere less than 5.
Survival estimates, including freedom from dPGD during the
dmission for transplantation, were derived by using the Kaplan–
eier method, and survivals across the lung perfusion groups were
ompared by using the log–rank test. Cox proportional hazards
egression24 was used to examine the effect of preservation
ethod on survival, after adjusting for potentially confounding
actors. A clinical review of the database was undertaken to
dentify the potentially important variables to include. The effect
f the chosen factors, together with the preservation method, was
valuated for the 3 epochs: early (30 days), late (30 days to 3
ears), and overall (3 years) survival. These time periods were
hosen to reflect the times when patients experience early and late
raft failure/dysfunction. The differential effect of lung perfusion
ethod on survival for transplantations with short (210 minutes),
edium (211–270 minutes and 270–330 minutes), and long
330 minutes) ischemic times was investigated through the in-
lusion of interaction terms. Transplantation center was accommo-
ated in 2 ways: (1) by including center as a covariate and (2) by
ember 2007
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TXtratification. The proportional hazards assumption was examined
or each model fitted. Results are presented as hazard ratios with
5% confidence intervals (CIs).
Freedom from dPGD was estimated by using the competing risks
ethod, and survival across the lung preservation groups was com-
ared by using the log–rank test. Length of intensive care unit stay
as compared by using the log–rank test, and negative binomial
egression25 was used to compare posttransplantation rejection rates
o 3 years across the groups after adjusting for follow-up time and
otential confounding factors (diagnosis, transplant type, cytomega-
ovirus [CMV]–positive organ given to a CMV-negative recipient,
lood group compatibility, ischemic time, audit year, and transplan-
ation center). Again, the differential effect of lung perfusion method
n rejection rates for transplantations with short, medium, and long
schemic times was investigated through the inclusion of interaction
erms. Time to first rejection episode, adjusting for the same potential
onfounding factors, was compared by using Cox proportional haz-
rds regression stratified by center.
All analyses were carried out with STATA software (release
.2; Stata Corp, College Station, Tex).
esults
e analyzed 681 primary isolated lung (345 single and 336
ilateral) transplantations. EC solution was used as the preser-
ation technique in 284 (42%), BA in 139 (20%), CC in 107
16%), and LPD solution in 151 (22%) transplantations.
Donor characteristics are reported in Table 1. Donor age,
ody mass index, and need for inotropes differed between
roups (P .01). Lungs preserved in EC and LPD solutions
ere from younger donors than lungs preserved with BA
nd CC, and lungs preserved with EC solution were from
onors with a lower median body mass index compared
ith those in the other groups. The need for inotropes was
reatest in the LPD group (39%), whereas in the EC and CC
roups, fewer than 20% of donors required inotropes.
Pretransplantation recipient characteristics are detailed in
able 2. Recipients of BA-perfused lungs had the highest
edian age (53 vs 51 years or lower in other groups) and
ere more likely to be taking prednisolone (56%) compared
ith recipients of other lungs. Recipients of LPD-preserved
ungs had the lowest rate of pretransplantation steroid use
36%), whereas in the EC and CC groups 48% and 49% of
atients were taking prednisolone, respectively (P  .008).
able 1. Donor characteristics
Euro–Collins solution
(n  284)
Blood album
(n  139)
ge (y) 35 (23–46) 40 (31–51)
emale sex (n) 128 (45%) 71 (51%)
MV positive (n)* 138 (49%) 66 (48%)
ody mass index 22.7 (20.8–24.5) 23.1 (21.4–24
notropic use (n) 52 (19%) 35 (27%)
MV, Cytomegalovirus. *Less than 5% missing data.he distribution by diagnosis differed between the groups; m
The Journal of Thoracicmphysema was the most prevalent diagnosis in all groups,
ollowed by pulmonary fibrosis in the EC, BA, and CC
roups and cystic fibrosis in the LPD group. Few en bloc
ouble-lung transplantations were carried out; in the EC
roup the majority of transplantations were single-lung
ransplantations, whereas in the other groups bilateral se-
uential lung grafts were more common.
The use of perfusion fluids has changed significantly
ver time (P  .001). Use of EC solution has decreased in
ecent years, whereas use of LPD solution has increased in
opularity (Figure 1). Similarly significant differences in
ndividual center preferences toward a particular perfusion
ethod were found (P  .001, Figure 2).
There were 70 deaths within 30 days and 166 deaths within
year, and 255 recipients died within 3 years of transplanta-
ion. The overall unadjusted 30-day, 1-year, and 3-year surviv-
ls for the whole cohort were 89.7% (95% CI, 87.2%–91.8%),
5.6% (95% CI, 72.1%–78.6%), and 58.1% (95% CI, 53.9%–
2.1%), respectively. The median follow-up for survivors was
years (lower quartile, 2.1 years). Patient survival by preser-
ation method, unadjusted for risk differences, is shown in
igure 3. Recipients of lungs perfused with BA had the lowest
-year survival (49.3%; 95% CI, 39.4%–58.4%), whereas re-
ipients of lungs perfused with LPD solution had the highest
urvival rate (62.3%; 95% CI, 51%–71.7%). The 13% survival
ifference across the groups was not statistically significant (P
.72).
Pretransplantation recipient factors included in the mul-
ivariate survival models were age group (grouped 16–40,
1–50, 51–55, and 55 years), sex, creatinine clearance,
iabetes, ventilation, history of previous thoracotomy, in-
ection, diagnosis group, and type of transplantation. Donor
isk factors included were donor age group (grouped 25,
6–35, 36–50, and 50 years), sex, inotrope use, diabetes,
MV mismatch, donor-recipient size mismatch (donor
ody surface area 80% of recipient body surface area),
lood group compatibility, organ ischemia time, and
hether the organs were retrieved by the transplanting
enter (organ exchange). Recipient sex was included as a
tratification variable because the proportional hazards as-
umption was not reasonable (P  .002 for the 30-day
Core cooling
(n  107)
Low potassium dextran
solution (n  151) P value
41 (29–51) 37 (23–48) .001
48 (45%) 70 (46%) .7
45 (45%) 67 (45%) .8
23.4 (21.8–26.1) 23.7 (21.6–26.0) .01
14 (14%) 45 (39%) .001in
.7)odel). The effect of preservation method on survival was
and Cardiovascular Surgery ● Volume 134, Number 5 1315
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1
TXimilar when adjusting for center and stratifying by center,
nd therefore only the stratified results are reported. For all
odels, the effects were consistent across the different
engths of ischemic time (ie, no interaction between perfu-
ion method and ischemic time was indicated; P  .81).
stimated hazard ratios for perfusion technique, plus the
ther prespecified factors included in the model, are detailed
n Tables 3 and 4, respectively. After controlling for these
respecified risk factors, perfusion technique was not iden-
ified as a significant independent predictor of recipient
ortality in all 3 epochs (P  .72, P  .27, and P  .70 for
0-day, 30-day to 3-year, and overall 3-year survival, re-
pectively). The proportional hazards assumption was ex-
mined for all models, and the assumption was a reasonable
ne for the 30-day to 3-year and overall 3-year models but
as violated for the 30-day model (0.048).
Freedom from dPGD was analyzed on a subset of 631
alidated records between July 1995 and December 2002.
here were 302 (48%) deaths in this group, of which 108
ccurred within the transplantation admission. Of these 108, 51
47%) were validated as dPGD. dPGD were 25 (9%) in lungs
able 2. Pretransplantation recipient characteristics
Euro–Collins solution
(n  284)
Blood
(n 
ge (y) 51 (38–56) 53 (45
emale sex (n) 127 (45%) 62 (45
ody mass index 22.0 (19.0–25.8) 22.3 (19
iagnostic group
Primary pulmonary
hypertension
9 (3%) 6 (4%
Pulmonary fibrosis 88 (31%) 37 (27
Cystic fibrosis 50 (18%) 16 (12
Bronchiectasis 11 (4%) 6 (4%
Emphysema 113 (40%) 69 (50
Other 13 (6%) 5 (4%
iabetes mellitus (n)* 13 (5%) 11 (8%
revious thoracotomy† (n)* 22 (8%) 21 (15
rednisolone (n)* 135 (48%) 77 (56
reatinine clearance
(mg · dL1 · m2)
79 (63–93) 80 (67
ome oxygen support (n)* 200 (71%) 103 (75
npatient at registration (n) 34 (12%) 17 (12
MV positive (n)* 162 (59%) 79 (58
reoperative infection‡ (n)* 72 (26%) 29 (22
ransplant type
Single lung 166 (58%) 66 (48
En bloc double lung 1 (1%) 1 (
Bilateral sequential lung 117 (41%) 72 (52
MV, Cytomegalovirus. *Less than 5% missing values. †Any operation on i
or nonpulmonary disease, such as esophageal, cardiac, vertebral, and ao
horacoscopic procedures), sternotomies, or mediastinotomies. ‡Microbio
or prophylaxis or presumed infection.reserved with EC solution, 12 (9%) in lung preserved with w
316 The Journal of Thoracic and Cardiovascular Surgery ● NovA, 8 (8%) in lungs preserved with CC, and 6 (5%) in lungs
reserved with LPD solution. There was no significant differ-
nce in dPGD between preservation techniques. Cumulative
ncidence of dPGD, as assessed by using the competing risks
ethod, is depicted in Figure 4 and Table 5.
The median intensive care unit stay was 3 days in the EC
roup (interquartile range [IQR], 1–7 days), 2 in the BA
roup (IQR, 1–8 days), 3 in the CC group (IQR, 1–14 days),
nd 2 in the LPD group (IQR, 1–7 days). There was no
ignificant difference in the median intensive care unit stay
mong the perfusion groups (P  .46), although differences
cross centers were found (P  .001). Center-specific me-
ian length of ICU stay ranged from 2 days (IQR, 1–2 days)
o 7 days (IQR, 4–13 days).
The analysis of posttransplantation rejection was restricted
o the subset of 629 patients undergoing transplantation after
pril 1996 because rejection data were not collected in the first
ear of the audit. Overall, 229 (36.4%) patients were free from
ejection at last follow-up, and 23 had experienced more than
episodes of rejection in the first 3 years after transplantation
median follow-up, 2.8 years). The overall crude incidence rate
in Core cooling
(n  107)
Low potassium dextran
solution (n  151) P value
51 (45–55) 50 (36–56) .04
47 (44%) 64 (42%) .9
6.7) 22.2 (18.6–25.6) 22.0 (19.1–25.9) .8
.014
4 (4%) 2 (1%)
20 (19%) 30 (20%)
14 (13%) 42 (28%)
4 (4%) 7 (5%)
61 (57%) 66 (44%)
4 (4%) 4 (3%)
5 (5%) 14 (9%) .2
9 (9%) 13 (9%) .1
50 (49%) 54 (36%) .008
84 (70–101) 81 (71–96) .09
86 (82%) 115 (77%) .2
11 (10%) 14 (9%) .8
60 (57%) 75 (50%) .4
30 (28%) 51 (35%) .1
47 (44%) 66 (44%) .001
6 (6%) 3 (2%)
54 (50%) 54 (52%)
oracic structures through a lateral thoracic incision, including operations
rgery. Does not include minimal-access operations (minithoracotomy and
lly confirmed infections only. Does not include patients taking antibioticsalbum
139)
–58)
%)
.3–2
)
%)
%)
)
%)
)
)
%)
%)
–97)
%)
%)
%)
%)
%)
1%)
%)
ntrath
rtic su
logicaas 0.72 rejection episodes per year. Rejection rates increased
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TXith increasing ischemic time (adjusted incidence rate ratio,
.10; 95% CI, 0.99–1.22; P  .067 per increase in category),
nd there was no evidence to suggest a differential effect with
ung perfusion method (P .45). Reported rejection rates have
hanged with time (P .0029); rates were lower in the period
rom 1998 through 2001 than at other times. The incidence was
igher among patients receiving a single lung graft compared
ith those receiving a bilateral graft (P  .007). Rejection
ates varied between perfusion techniques but not consistentlyThe Journal of Thoraciccross centers (test for differential effect, P .012). However,
here was no evidence to suggest time to first rejection had
hanged significantly over time (P  .39) or that it differed
ith ischemic time (P .92) or with lung perfusion technique
P  .11).
iscussion
his study suggests that currently used lung preservation tech-
iques do not affect early or midterm survival rates, incidence
Figure 1. Use of preservation fluids
over time.
Figure 2. Use of preservation fluids by
transplantation center for lungs re-
trieved by the transplanting center and
lungs retrieved by another center (ex-
changed).and Cardiovascular Surgery ● Volume 134, Number 5 1317
op
w
T
w
A
d
L
h
t
i
c
T
R
A
C
D
P
P
P
T
D
C
m
Cardiothoracic Transplantation Ganesh et al
1
TXf dPGD, ICU length of stay, or rejection rate. Regardless of
reservation technique, rejection incidence appears to increase
ith ischemic time, but time to first rejection is not affected.
hese data are derived from a relatively large cohort of patients
ho underwent LTx with 4 different preservation techniques.
lthough modified EC solution was the main perfusate used
able 3. Recipient factors*
Early (30-d) survival
isk factor
Hazard
ratio 95% CI
P
va
ge group 1.13 0.84–1.50 .4
reatinine clearance 1.78 0.74–3.28 .2
iabetes mellitus 2.13 0.69–6.62 .1
reoperative ventilation† 5.01 0.88–28.4 .0
revious thoracotomy‡ 1.08 0.49–2.37 .4
reoperative infection‡ 1.42 0.72–2.80 .5
ransplant type 1.00
Single lung 2.35  .5
En bloc double lung 1.10 0.48–11.4
Bilateral sequential lung 0.59–2.07
iagnosis group
Pulmonary fibrosis 1.00  .0
Primary pulmonary hypertension 4.72 1.78–12.5
Cystic fibrosis 0.20 0.06–0.68
Bronchiectasis 0.16 0.02–1.40
Emphysema 0.54 0.28–1.01
Others 1.09 0.36–3.21
I, Confidence interval. *Stratified by transplantation center and recipient s
issing on 2 patients. ‡Adjusted for missing data.
318 The Journal of Thoracic and Cardiovascular Surgery ● Novuring the study period, its dominance is being subsumed by
PD solution. In contrast to a number of previous reports that
ave suggested improved survival with LPD solution,3,6,7,26,27
his has not been confirmed in a current study.28 LPD solution
s thought to be beneficial because of the low potassium
oncentration, which causes less endothelial injury, and the
Figure 3. Patient survival by lung pres-
ervation method (P  .7).
Late (30-d to 3-y) survival Overall (3-y) survival
Hazard
ratio 95% CI
P
value
Hazard
ratio 95% CI
P
value
1.12 0.93–1.34 .23 1.14 0.97–1.33 .09
1.15 0.60–2.20 .66 1.30 0.78–2.16 .31
1.39 0.67–2.86 .37 1.58 0.87–2.90 .13
1.44 0.28–7.16 .66 2.33 0.73–7.42 .15
1.32 0.80–2.17 .34 1.27 0.84–1.92 .20
1.32 0.88–1.98 .14 1.31 0.92–1.84 .18
1.00  .69 1.00  .51
1.27 0.35–4.48 1.64 0.62–4.35
0.87 0.58–1.29 0.94 0.67–1.32
1.00  .14 1.00  .007
0.33 0.0–1.48 1.48 0.72–3.03
0.79 0.37–1.66 0.56 0.30–1.04
0.33 0.12–0.94 0.30 0.12–0.76
0.83 0.56–1.24 0.74 0.53–1.03
1.45 0.66–3.16 1.31 0.70–2.46
nly 5 patients were ventilated before transplantation, and information waslue
2
0
9
7
5
7
7
01
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TXemorheologic properties of dextran.28 Despite our negative
nding, there was a trend toward improved longer-term sur-
ival in the LPD group and lower cumulative incidence of
PGD. It might be that the study was numerically underpow-
red to demonstrate a significant difference.
able 4. Donor factors*
isk factors
Early (30-d) survival
Hazard
ratio 95% CI P value
ung perfusion method
Euro–Collins solution 1.00  .72
Blood albumin 0.60 0.24–1.45
Core cooling 0.84 0.31–2.28
Low potassium
dextran solution
0.82 0.38–1.75
onor age group 0.90 0.70–1.15 .41
emale donor 0.92 0.51–1.64 .78
onor inotrope use† 0.93 0.48–1.81 .12
onor diabetes‡ 0.89 0.10–8.04 .19
MV status mismatch†‡ 1.61 0.83–3.12 .13
lood group variance 0.71 0.31–1.61 .42
ize mismatch 2.59 0.70–9.59 .15
rgan ischemic time
210 min 1.00  .95
211–270 min 1.19 0.57–2.48
270–330 min 1.06 0.47–2.35
330 min 0.96 0.36–2.54
xchanged organ(s) 0.60 0.33–1.08 .09
I, Confidence interval; CMV, cytomegalovirus. *Stratified by transplanta
ositive donor, cytomegalovirus-negative recipient.The Journal of ThoracicThabut and colleagues2 analyzed the effects of intracel-
ular (EC and University of Wisconsin solution) versus
xtracellular (BA and Celsior) solutions and identified that
xtracellular preservation solutions had a lower 30-day in-
idence of reimplantation edema after adjusting for graft
Figure 4. Deaths caused by primary
graft dysfunction by lung preservation
method (P  .6).
Late (30-d to 3-y) survival Overall (3-y) survival
rd
o 95% CI P value
Hazard
ratio 95% CI P value
 .27 1.00  .70
0.98–2.55 1.23 0.81–1.86
0.76–2.77 1.28 0.75–2.18
0.77–2.03 1.15 0.77–1.72
0.95–1.30 .19 1.04 0.91–1.19 .54
0.50–1.07 .11 0.85 0.62–1.16 .30
0.48–1.06 .23 0.79 0.57–1.11 .14
0.85–6.38 .17 1.78 0.72–4.37 .45
1.06–2.34 .06 1.52 1.08–2.12 .03
0.54–1.31 .45 0.80 0.54–1.18 .26
0.56–5.60 .32 1.86 0.79–4.34 .15
 .11 1.00  .30
0.80–1.85 1.19 0.83–1.71
0.84–2.18 1.24 0.82–1.85
1.15–3.58 1.61 0.99–2.62
0.54–1.09 .13 0.74 0.55–1.00 .05
enter and recipient sex. †Adjusted for missing data. ‡Cytomegalovirus-Haza
rati
1.00
1.58
1.45
1.25
1.11
0.73
0.71
2.34
1.57
0.84
1.78
1.00
1.22
1.35
2.03
0.76
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1
TXschemic time. In contrast, our study did not identify any
ifference in survival at 30 days or 3 years among the
ifferent perfusion groups after adjusting for risk factors,
ncluding graft ischemic time. We also did not find any
ifference in dPGD between the extracellular and intracel-
ular types of preservation solutions in a validated subset of
ecipients. This finding is confirmed by a recently published
omparison of LPD and EC solution on a smaller of subset
f patients, although the authors did find a lower PGD
nternational Society for Heart and Lung Transplantation
rade III incidence at T24 in the LPD group.10
The overall unadjusted 1- and 3-year survivals in our
ohort reflect worldwide trends.29 Recipients of lungs pre-
erved with LPD solution had a marginally higher unad-
usted survival over other recipients, but this difference was
ot seen after adjusting for other risk factors. Analysis of
ejection episodes was restricted to a smaller subset of
atients, and rejection rates increased with increasing isch-
mic time. We did not find any difference in rejection
pisodes among the perfusion groups, although we did
dentify a higher incidence of rejection in single-lung grafts.
hether this correlates with a decreased survival in single-
ung grafts is beyond the scope of this study.
Our study has a number of limitations. Although com-
rising more than 600 patients, it might still be too small to
emonstrate small differences in survival. Also, we could
ot report the full incidence or severity of PGD per se, only
eath attributable to PGD. However, ICU length of stay,
hich can be regarded as a surrogate measure of early graft
unction, was not different. Nevertheless, nonfatal PGD
ight be an important factor in determining graft longevity,
nd early graft dysfunction has been previously reported to
e a risk factor for rejection, BOS, and late mortality.1-3 We
o not have data on reperfusion strategies, such as con-
rolled pressure reperfusion, nitric oxide, or prostaglandin
nhalation, used during the study period or whether supple-
ental retrograde flush perfusion was used. We have also
ot been able to assess the incidence or severity of BOS.
Strong center preferences for different perfusion tech-
able 5. Summary of survival data by preservation techniq
30-d survival (95% CI) 1-y survival (95%
uro–Collins solution
(n  284)
88% (83.7%–91.3%) 74.3% (68.8%–79
lood albumin
(n  139)
92.1% (86.2%–95.5%) 74% (65.8%–80
ore cooling (n  107) 89.7% (82.2%–94.2%) 79.4% (70.4%–85
ow potassium dextran
solution (n  151)
90.7% (84.9%–94.4%) 76.6% (69%–82.6
value .57 .71
I, Confidence interval; dPGD, death from primary graft dysfunction.iques, perioperative management protocols, and differences r
320 The Journal of Thoracic and Cardiovascular Surgery ● Novn protocols for monitoring and identifying posttransplantation
ejection that exist between centers limit the ability of the study
o assess the independent effect of perfusion technique on
urvival, the incidence of rejection, and BOS. However, 45%
f donor lungs were exchanged between centers, which re-
uced the confounding between centers and the preservation
ethod. A volume-related effect was suggested for survival
rom 30 days to 3 years, with centers carrying out the greatest
umber of operations having the highest conditional survival
P .04), but the effect of preservation method on survival did
ot vary significantly with volume (P  .12). Ischemic times
re recorded consistently across centers and are not con-
ounded with center or perfusion technique, and each center is
esponsible for retrieving organs from a specified region of the
ountry and will use the organ locally where possible. Longer
schemic times are associated with greater organ injury, which
ppears to lead to increased incidence but not earlier rejection.
ur study also has limitations in the form of absence of donor
nd recipient blood gas measurements. Thus, we cannot fully
nalyze or quantify the effect of preservation technique on
arly graft function. Because a temporary deterioration in gas
xchange between donor and recipient is an almost constant
eature of lung transplantation, the extent of this deterioration
ight become a useful index of preservation quality.30
In conclusion, in this study lung preservation technique
id not affect 30-day, 1-year, or 3-year survivals; freedom
rom death attributable to PGD; or rejection rate. Although
mproved outcomes for LPD solution might become appar-
nt in time, the case for the superiority of one technique
ver another remains to be proved, and it is clear that this
eeds to be addressed in multicenter randomized controlled
rials with substantial numbers of patients using subtler end
oints than survival. In the absence of such trials, audits,
uch as the UKCTA, require more detailed data accrual of
retransplantation and posttransplantation donor lung func-
ion, together with robust criteria to determine the incidence
nd severity of PGD.31 Such audit data are likely to improve
ur understanding of the effect of different preservation and
3-y survival (95% CI)
Cumulative incidence of dPGD (n, last day
of occurrence [95% CI])
60.7% (54.8%–66.1%) n 284, 247 d; 8.8% (5.9%–12.5%)
49.3% (39.4%–58.4%) n 129, 83 d; 8.4% (3.9%–15.1%)
52.3% (40.2%–63.1%) n 95, 90 d; 4.9% (2.0%–9.7%)
62.3% (51%–71.7%) n 123, 147 d; 9.3% (5.1%–15.1%)
.72 .58ue
CI)
%)
.5%)
.9%)
%)eperfusion techniques on lung transplantation outcomes.
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